Vaccination

Germany's CureVac ditches first-generation COVID jab

Germany's CureVac said Tuesday it is no longer seeking European regulatory approval for its coronavirus vaccine, and will focus instead on a more promising second-generation jab.

Other

Roche sees pharma market recovering from COVID

Swiss pharmaceutical firm Roche said Thursday that drug sales have begun to recover from a COVID-induced slump as it confirmed forecasts for a modest increase in sales for the year as a whole.

Diseases, Conditions, Syndromes

Interim trial data shows low effectiveness for CureVac shot

German vaccine maker CureVac said Wednesday that interim data from late-stage testing of its coronavirus shot show a comparatively low effectiveness in protecting people against COVID-19.

Pediatrics

Novavax starts COVID-19 vaccine trials on children

US biotech firm Novavax said Monday it had started clinical trials of its proposed COVID-19 vaccine on children, in a program that will involve up to 3,000 adolescents aged 12-17.

Vaccination

EU hints it might not order AstraZeneca jab again

The EU's internal markets commissioner Thierry Breton hinted Sunday that the bloc might decide not to order AstraZeneca's coronavirus jab again following delays in delivering the first batches of the vaccine.

page 2 from 7